Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: Results of the TIrofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial

Circulation

Volumn 107, Issue 11, 2003, Pages 1497-1501

  Lee, David P ^a   Herity, Niall A ^a   Hiatt, Bonnie L ^a   Fearon, William F ^a   Rezaee, Mehrdad ^a   Carter, Andrew J ^a   Huston, Michelle ^b   Schreiber, Donald ^b   DiBattiste, Peter M ^c   Yeung, Alan C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angioplasty; Myocardial infarction; Platelets

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADJUVANT THERAPY; ADULT; AGED; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; CORONARY STENT; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PILOT STUDY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHEMOTHERAPY, ADJUVANT; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE;

EID: 0037465842     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000056120.00513.7A     Document Type: Article

References (32)

1. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.
2. The GUSTO IIb Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 1997;336:1621-1628.
3. Zijlstra F, Hoomtje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341:1413-1419.
4. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001;104:636-641.
5. Tofler GH. Triggering and the pathophysiology of acute coronary syndromes. Am Heart J. 1997;134:S55-S61.
6. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999;341:1949-1956.
7. Topol EJ, for the the GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
8. Makkar R, Goff B, Eigler N, et al. Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of the ReoMI pilot study. Cath Card Intervent. 1999;48:430-434.
9. Brener S, Barr LA, Burchenal JE, et al, for the RAPPORT Investigators. Randomized, placebo-controlled trial of glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-741.
10. Van den Merkhof LFM, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary transluminal coronary angioplasty: results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999;33:1528-1532.
11. Montalescot G, Barragan P, Wittenberg O, et al, for the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2002;344:1895-1903.
12. Stone GW, Grines CL, Cox DA, et al, for the CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
13. Cutlip DE, Cove CJ, Irons D, et al. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedural outcomes. Am J Cardiol. 2001;88:62-64.
14. The PRISM Study Investigators. Comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
15. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
16. Cannon CP, for the TIMI-18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
17. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
18. Topol E, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
19. Bovill EG, Terrin ML, Stump DC, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparill, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. Ann Intern Med. 1991;115:256-265.
20. TIMI Study Group. The Thombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
21. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879-888.
22. Gibson CM, Cannon CP, Murphy SA, et al. The relationship of the TIMI myocardial perfusion grade to mortality flowing thrombolytic administration. Circulation. 2000;101:125-130.
23. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
24. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
25. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT). Lancet. 2000;356:2037-2044.
26. The PURSUIT Study Group. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized, placebo-controlled, clinical trial. N Engl J Med. 1998;339:436-443.
27. Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002;89:647-650.
28. Neumann F-J, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol. 2001;37:1323-1328.
29. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al, for the TARGET Investigators. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet. 2002;360:355-360.
30. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 2002;90:1421-1423.
31. Gibson CM, Murphy SA, Marble SJ, et al, for the TIMI Study Group. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol. 2001;87:450-453.
32. Gibson CM, Cannon CP, Murphy SA, et al, for the TIMI Study Group. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909-1913.